EGFR and depressive disorder: This study further identified HSP90AA1, ESR1, AKT1, VCAM1, EGFR, CDK1, MAPK1, CDK2, MYC, HSPB1, and HSPA5 as the key targets of YZQX in the treatment of AD with comorbid depression.